Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

NCT02960204 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Cirrhosis
Portal Hypertension
Non-alcoholic Steatohepatitis

Interventions

DRUG: Emricasan
DRUG: Placebo

Sponsor

Histogen